Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Haematopoietic Cell Transplantation: Extended Follow-Up of the Phase 2 Multi-Cohort CheckMate 205 Study

被引：0
|
作者：
Collins, G. [1 ]
Armand, P. [2 ]
Engert, A. [3 ]
Younes, A. [4 ]
Lee, H. J. [5 ]
Santoro, A. [6 ]
Zinzani, P. L. [7 ]
Timmerman, J. [8 ]
Ramchandren, R. [9 ]
Cohen, J. [10 ]
De Boer, J. P. [11 ]
Savage, K. [12 ]
Kuruvilla, J. [13 ,14 ]
Trneny, M. [15 ,16 ]
Shipp, M. [2 ]
Sacchi, M. [17 ]
Sumbul, A. [17 ]
Ansell, S. [18 ]
机构：
[1] Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Hosp Cologne, Cologne, Germany
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Humanitas Univ, Humanitas Canc Ctr, Milan, Italy
[7] Univ Bologna, Inst Hematol L e A Seragnoli, Bologna, Italy
[8] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA USA
[9] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[10] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[11] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[12] BC Canc, Vancouver, BC, Canada
[13] Univ Toronto, Vancouver, BC, Canada
[14] Princess Margaret Canc Ctr, Vancouver, BC, Canada
[15] Charles Univ Prague, Prague, Czech Republic
[16] Gen Univ Hosp Prague, Prague, Czech Republic
[17] Bristol Myers Squibb, Princeton, NJ USA
[18] Mayo Clin, Rochester, MN USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 185卷
关键词：
checkpoint inhibitor; Hodgkin lymphoma; long-term outcomes; programmed death-1;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH19-PO-0
引用
收藏
页码：80 / 81
页数：2
相关论文
共 50 条
  • [31] Safety and efficacy of allogeneic stem cell transplantation after nivolumab therapy for patients with relapsed/refractory classical Hodgkin lymphoma
    Beynarovich, A.
    Lepik, K.
    Mikhailova, N.
    Kondakova, E.
    Zalyalov, Y.
    Moiseev, I.
    Afanasyev, B.
    ANNALS OF ONCOLOGY, 2019, 30 : 22 - +
  • [32] Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma
    Giaccone, L.
    Festuccia, M.
    Zallio, F.
    Sorasio, R.
    Brunello, L.
    Maffini, E.
    Dellacasa, C.
    Passera, R.
    Iovino, G.
    Aydin, S.
    Boccadoro, M.
    Vitolo, U.
    Mordini, N.
    Pini, M.
    Busca, A.
    Bruno, B.
    BONE MARROW TRANSPLANTATION, 2017, 52 (08) : 1208 - 1211
  • [33] Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma
    L Giaccone
    M Festuccia
    F Zallio
    R Sorasio
    L Brunello
    E Maffini
    C Dellacasa
    R Passera
    G Iovino
    S Aydin
    M Boccadoro
    U Vitolo
    N Mordini
    M Pini
    A Busca
    B Bruno
    Bone Marrow Transplantation, 2017, 52 : 1208 - 1211
  • [34] Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study (CA209-039)
    Ansell, Stephen
    Armand, Philippe
    Timmerman, John M.
    Shipp, Margaret A.
    Garelik, M. Brigid Bradley
    Zhu, Lili
    Lesokhin, Alexander M.
    BLOOD, 2015, 126 (23)
  • [35] TIME-EXTENDED MULTI-AGENT CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY OR RELAPSED HODGKIN'S LYMPHOMA A LONG-TERM FOLLOW-UP OF A PILOT STUDY
    Kata, D.
    Kata, D.
    Giebel, S.
    Grosicki, S.
    Kachel, L.
    Sadus-Wojciechowska, M.
    Krawczyk-Kulis, M.
    Wojnar, J.
    Holowiecki, J.
    Kyrcz-Krzemien, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 325 - 325
  • [36] Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study
    Ramchandren, Radhakrishnan
    Fanale, Michelle A.
    Rueda, Antonio
    Armand, Philippe
    Trneny, Marek
    Feldman, Tatyana A.
    Ansell, Stephen M.
    Provencio, Mariano
    Jaeger, Ulrich
    Cohen, Jonathon B.
    Savage, Kerry J.
    Willenbacher, Wolfgang
    Sacchi, Mariana
    Sumbul, Anne
    Domenech, Eva Domingo
    BLOOD, 2017, 130
  • [37] Patient Subgroup Analysis of Quality-of-Life Outcomes in Checkmate 205, a Phase 2 Study of Nivolumab in Patients with Classical Hodgkin Lymphoma
    Engert, Andreas
    Taylor, Fiona
    Bennett, Bryan
    Hirji, Ishan
    Cocks, Kim
    McDonald, Jeffrey
    Mann, Erin
    Kato, Kazunobu
    Cella, David
    BLOOD, 2016, 128 (22)
  • [38] Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience
    Roerden, Malte
    Soekler, Martin
    Kanz, Lothar
    Bethge, Wolfgang
    Vogel, Wichard
    Walz, Juliane S.
    ANNALS OF HEMATOLOGY, 2020, 99 (02) : 265 - 276
  • [39] CheckMate 436: Extended Follow-Up from the Phase 2 Study Investigating Nivolumab Plus Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (R/R PMBL)
    Zinzani, Pier Luigi
    Santoro, Armando
    Gritti, Giuseppe
    Brice, Pauline
    Barr, Paul
    Cunningham, David
    Kline, Justin
    Johnson, Nathalie
    Mehta-Shah, Neha
    Fanale, Michelle
    Francis, Stephen
    Moskowitz, Alison
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S398 - S399
  • [40] A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation
    Chen, Clara
    Armand, Philippe
    Rogula, Basia
    Johnston, Karissa
    Peterson, Derek
    Connors, Joseph M.
    Lozano-Ortega, Greta
    BLOOD, 2019, 134
12345